A <scp>WIN</scp> Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non‐small cell lung cancer-Reference-Cited by-同舟云学术

A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non‐small cell lung cancer

Published:2022-03-20 Issue:14 Volume:11 Page:2790-2800
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Solomon Benjamin¹^ORCID,Callejo Ana²,Bar Jair³,Berchem Guy⁴,Bazhenova Lyudmila⁵,Saintigny Pierre⁶,Wunder Fanny⁷,Raynaud Jacques⁸,Girard Nicolas⁹,Lee J. Jack¹⁰,Sulaiman Raed¹,Prouse Bruce¹,Bresson Catherine⁷^ORCID,Ventura Hila¹¹,Magidi Shai⁷,Rubin Eitan¹¹,Young Brandon¹²,Onn Amir³,Leyland‐Jones Brian⁷,Schilsky Richard L.⁷,Lazar Vladimir⁷,Felip Enriqueta²,Kurzrock Razelle⁵^ORCID

Affiliation:

1. Avera Cancer Institute Sioux Falls South Dakota USA

2. Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO) Barcelona Spain

3. Chaim Sheba Medical Center Tel Hashomer Israel

4. Centre Hospitalier de Luxembourg Luxembourg Institute of Health Luxembourg City Luxemburg

5. University of California San Diego Moores Cancer Center San Diego California USA

6. Centre Léon Bérard, Cancer Research Center of Lyon University of Lyon Lyon France

7. Worldwide Innovative Network (WIN) Association ‐ WIN Consortium Villejuif France

8. ARC Foundation for cancer research Villejuif France

9. Institut Curie Paris France

10. The University of Texas MD Anderson Cancer Center Houston Texas USA

11. Ben‐Gurion University of the Negev Be'er Sheva Israel